Bel

Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for currently untreatable eye diseases involving retinal degeneration and metabolic diseases. The company's lead candidate, tinlarebant (LBS-008), is an oral small molecule designed to reduce the accumulation of toxins in the eye that cause retinal degeneration. Tinlarebant is currently being evaluated in global Phase 3 clinical trials for both adolescent Stargardt disease and geographic atrophy secondary to dry age-related macular degeneration. Belite Bio aims to provide the first FDA-approved oral treatment for these progressive and blinding conditions.